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The Impact of Diabetic Retinopathy and Diabetic
Macular Edema on Health-Related Quality of Life in
Type 1 and Type 2 Diabetes
Eva K. Fenwick,1 Jing Xie,1 Julie Ratcliffe,2 Konrad Pesudovs,3 Robert P. Finger,1
Tien Y. Wong,1,4 and Ecosse L. Lamoureux1,4
PURPOSE. To assess the impact of diabetic retinopathy (DR) and
diabetic macular edema (DME) on health-related quality of life
(HRQoL) in type 1 and type 2 diabetes using the EuroQoL
EQ-5D generic multi-attribute utility instrument (MAUI).
METHODS. In this cross-sectional study, 577 patients with dia-
betes were recruited from specialized eye clinics in Melbourne,
Australia. Each patient underwent clinical, biochemical, and
anthropometric assessments. The severity of combined DR and
DME (no DR/DME; mild NPDR [nonproliferative DR (NPDR)]
and/or mild DME; moderate NPDR and/or moderate DME; and
vision-threatening DR (VTDR) (severe NPDR or PDR and/or
severe DME) in the worse eye was calculated. EQ-5D utility
measures were the main outcome. Because the distribution of
the utility measures was skewed, independent associations
were explored using multivariate quantile regression models
(five quintiles, namely 15th, 30th, 45th, 60th, 75th) ranging
from poorest to highest HRQoL.
RESULTS. Median age of the participants was 66 years (range,
26–90 years). Of the 577 participants, 223 (38.7%) had no
DR/DME, 35 (6.1%) had mild NPDR/DME, 127 (22.0%) had
moderate NPDR/DME, and 192 (33.3%) had VTDR. In adjusted
models, neither presence nor severity of DR/DME was signifi-
cantly associated with any quantile of the EQ-5D. In contrast,
the presence of diabetic complications (other than DR) ( 
0.153; SE  0.052; P  0.001), other nonocular comorbidi-
ties (0.115; SE 0.038; P 0.01), and higher body mass
index (0.007; SE 0.002; P 0.001) were all associated
with worse HRQoL.
CONCLUSIONS. Using a generic MAUI, the EQ-5D, the authors
found that the presence or severity of DR/DME and concomi-
tant vision loss were not associated with any quantile of
HRQoL. These findings suggest that the EQ-5D lacks sensitivity
in assessing the impact of the severity of DR/DME on HRQoL
parameters and that condition-specific instruments may better
capture the full impact of the association. (Invest Ophthalmol
Vis Sci. 2012;53:677–684) DOI:10.1167/iovs.11-8992
Diabetic retinopathy (DR) is a common microvascular com-plication of diabetes.1 In its early nonproliferative stages
there are few visual symptoms; however, as the disease pro-
gresses to vision-threatening stages (severe nonproliferative DR
[NPDR] and proliferative DR [PDR]), significant vision loss can
occur. Diabetic macular edema (DME), which can occur at any
stage, affects central visual acuity.2 After 20 years of living with
diabetes, most patients will have some degree of DR.2,3
As shown by our group, the impact of DR and associated
vision impairment on health-related quality of life (HRQoL) is
considerable.4,5 One common way of assessing HRQoL for
economic evaluation is through the estimation of utility mea-
sures for the calculation of quality-adjusted life years (QALYs).
Utility measures have typically been generated by using elici-
tation methods, such as the time tradeoff (TTO) and standard
gamble (SG), directly with patient cohorts. Studies using TTO
and SG have shown that utility tends to decrease steadily with
worsening visual acuity resulting from DR.6–14 However, there
are limitations associated with TTO and SG elicitation methods.
For example, utility values can be influenced by time prefer-
ence and duration effects in TTO methodology, whereas SG
utility values may be affected by patients’ attitudes to risk.15 An
alternative method for generating utility measures for the cal-
culation of QALYs is to use a multi-attribute utility instrument
(MAUI) for measuring and valuing HRQoL, such as the EuroQol
EQ-5D.16 MAUIs (including the EQ-5D) consist of two main
elements: a descriptive system composed of several attributes
describing HRQoL with associated levels of increasing severity
and a scoring algorithm for assigning utility values to each
health state described by the instrument.17
Research into the impact of DR on HRQoL using the EQ-5D,
however, has produced inconsistent findings. These discrep-
ancies may be due to differing sample populations, exposure
variables, or generic utility measures lacking sensitivity to eval-
uate the specific burden of DR-induced vision loss.18 Inconsis-
tent findings could also be associated with the use of inappro-
priate statistical methods (i.e., linear regression models) to
analyze utility data that are generally skewed and have ceiling
effects. In contrast, quantile regression models, which are
based on minimizing least absolute deviations and its estimates,
are more robust.19 Quantile regression analyzes the similarity
or dissimilarity of regression coefficients at different points in
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the distribution of the dependent variable, which in this case is
represented by the EQ-5D utilities.
Given the new treatment modalities for DR such as antivas-
cular endothelial growth factor (VEGF) therapy, clinical trials
will be needed to evaluate them against traditional methods of
treatment, not only in terms of clinical outcomes but also from
the patient’s perspective and from a cost-effectiveness view-
point. Using the EQ-5D, we assessed the impact of the pres-
ence and severity of DR and DME and associated vision loss on
HRQoL. To overcome some of the shortcomings of previous
studies, we recruited a large clinical sample of patients across
the spectrum of DR and applied a robust statistical technique—
quantile regression analysis—to analyze our EQ-5D data.
METHODS
Study Design and Participants
English speaking adults with diabetes were recruited into the Diabetes
Management Project (DMP), a large longitudinal study conducted in
Melbourne, Australia, from March 2009 to December 2010. Cross-
sectional data from the baseline phase are presented here. The meth-
odology of DMP has been described previously.20 In brief, participants
were recruited primarily from general and specialized eye clinics at the
Royal Victorian Eye and Ear Hospital (RVEEH). Eligible participants
included those who were 18 years or older, free of significant hearing
and cognitive impairment, and living independently. Each participant
provided written informed consent. Ethical approval for the DMP was
provided by the RVEEH Human Research and Ethics Committee (08/
815H), and the DMP protocol adhered to the tenets of the Declaration
of Helsinki.
Assessment of Health-Related Quality of Life
General HRQoL was measured using the EQ-5D MAUI.16 The EQ-5D is
a descriptive system that covers five dimensions of self-reported health:
mobility, self-care, usual activity, pain/discomfort, and anxiety/depres-
sion. Each dimension has three response categories: no problems,
some problems, and extreme problems. For example, a result of 11222
indicates no problems with mobility and self-care but some problems
with the other three dimensions. The 243 health states defined by the
EQ-5D responses were translated to EQ-5D utility scores using available
values sets that have been derived from large population-based sur-
veys.21,22 The scale of the utility index ranges between 0.0 and 1.0,
where 0.0 represents death and 1.0 represents full health. States that
are considered worse than death are represented by negative utility
values. Given that no publicly available value set exists for the Austra-
lian population, we conducted two analyses, the first using the United
Kingdom value set21 (TTO valuation method) and the second using the
New Zealand value set22 (visual analog scale (VAS) valuation method).
Because the findings were similar, only data using utility values derived
from the UK value set are reported in this study.
Assessment of Diabetic Retinopathy and
Vision Impairment
DR and DME were assessed using dilated fundus photography. Right
and left macular and optic disc fields (45° view) for each participant
were imaged using a nonmydriatic retinal camera (CR6–45NM; Canon,
Tokyo, Japan). Using the worse eye, we categorized the severity of DR
using the ETDRS definition as no DR  13–15, mild NPDR  20,
moderate NPDR  31–41, severe NPDR  51, and PDR  60–80; the
severity of DME using the American Academy of Ophthalmology clas-
sification23 as no DME  10/20, mild DME  30, moderate DME  40,
and severe DME 50; and the severity of combined DR/DME as no DR
and no DME, mild NPDR and/or mild DME, moderate NPDR and/or
moderate DME, and VTDR (severe NPDR, PDR, and/or severe DME.
Given that the results for the severity of DR and DME separately were
similar to the combined DR/DME categorization, we report data for the
latter group only. Ungradable fundus photographs attributed to poor
image quality or opacity in the media were excluded from the analysis.
Presenting distance uniocular and binocular visual acuity were
assessed using a 3-m LogMAR chart. We collapsed presenting visual
acuity (better eye) into two categories: 6/12 or better representing no
vision impairment and worse than 6/12 representing vision impair-
ment. Although this is a reasonably crude division, it allowed us a basic
understanding of the association between vision impairment and
EQ-5D utility score. We also examined the relationship between pre-
senting visual acuity as a continuous variable and the EQ-5D utility
score (data not shown) to ensure we were not overlooking an impor-
tant association; however, the results were nonsignificant and did not
improve the model fit.
Assessment of Other Risk Factors
Participants underwent a comprehensive assessment that included a
range of clinical, biochemical, and anthropometric measures and ques-
tionnaires on lifestyle, psychosocial factors and quality of life. The main
outcome was EQ-5D utility as an indicator of HRQoL. Key covariables
included age (years), sex, duration of diabetes (years), insulin use,
presence of one or more general comorbidities, presence of diabetic
complications other than DR/DME (including diabetic neuropathy,
diabetic nephropathy, and peripheral vascular disease), educational
attainment, household income, marital status, HbA1c (%), fasting
plasma glucose (mg/dL), HDL cholesterol (mg/dL), systolic and dia-
stolic blood pressure (SBP and DBP; mm Hg), body mass index (BMI;
kg/m2), and smoking status.
Statistical Analysis
Statistical analyses were undertaken (Stata/SE 11; StataCorp LP, College
Station, TX). Initially, the descriptive data from the EQ-5D question-
naire were converted to utilities using the scoring algorithms provided
by the EuroQoL group for the United Kingdom and the New Zealand
general population groups, respectively. Normality of the variables was
examined using box plots, Kolmogorov-Smirnov test, and Shapiro-
Wilks test. Clinical and sociodemographic characteristics of the study
participants were summarized using mean and SD for normally distrib-
uted variables, median and interquartile range (IQR) for nonnormally
distributed and count variables, and proportions for categorical vari-
ables. The 2 statistical test was used to analyze differences in propor-
tions between groups. Comparisons of mean and median values were
conducted using an independent samples t-test or two-sample Wil-
coxon rank-sum (Mann-Whitney U) test.
As anticipated, the distribution of the EQ-5D utility scores was
positively skewed, and a ceiling effect was evident, with 28% of
participants scoring full health (1.0) (Fig. 1). As indicated earlier, this
is not an uncommon finding with application of the EQ-5D24,25; how-
ever, it means that the true variation in HRQoL among those scoring
full health may not adequately be captured. This is because traditional
regression analysis focuses on the mean, in which the relationship
between the outcome (EQ-5D) and predictors (e.g., age, sex, DR) are
summarized by describing the mean of the outcome (EQ-5D) for each
fixed value of the predictors. However, traditional regression analysis
has inherent limitations. First, when summarizing the responses for
fixed values of predictor variables, a traditional regression model can-
not be readily extended to noncentral locations, which is precisely
where the interests of social science research often reside. For in-
stance, studies using the EQ-5D have intrinsic interest in the poorer
outcomes (lower tail), and traditional regression analysis cannot ad-
dress these questions efficiently and may even miss the point of the
research altogether. Second, the model assumptions are not always
met in the real world, which results in biased and inappropriate
estimates. Third, traditional regression analysis cannot reflect how
changes in the predictor variables affect the underlying shape of the
distribution of the outcome (EQ-5D).26
Because the distribution of the EQ-5D was skewed in our study
(Fig. 2), it cannot be adequately approximated by the usual parametric
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distribution functions. Therefore, using an ordinal least squares model
or indeed other models such as the Tobit or CLAD model, which have
also been used in EQ-5D related research,24,27,28 would be problematic
because these models all assume that the residuals are normally dis-
tributed. Moreover, the Tobit and CLAD models use an underlying
latent variable with a normal or other distribution, and this has been
criticized because these assumptions are unrealistic and cause a biased
estimation.
Quantile regression, on the other hand, is a statistical technique
that aims to estimate and conduct inference about conditional quantile
functions. Quantile regression methods offer a mechanism for estimat-
ing models for the conditional median function and the full range of
other conditional quantile functions. Given that multiple quantiles can
be modeled, it is possible to achieve a more complete understanding of
how the response distribution is affected by predictors, including
information about shape change. A set of equally spaced conditional
quantiles (e.g., every 5% or 1% of the population) can characterize the
shape of the conditional distribution in addition to its central location.
By supplementing the estimation of conditional mean functions with
techniques for estimating an entire family of conditional quantile func-
tions, quantile regression is capable of providing a more complete
statistical analysis of the stochastic relationships among random vari-
ables. Unlike linear regression, quantile regression is not limited to
explaining the mean of the EQ-5D, and it can be used to explain the
determinants of the EQ-5D at any point in its distribution.29
Therefore, the relationships among presence and severity of DR
and DME, vision impairment, and other sociodemographic and clinical
covariates and HRQoL were examined using a multivariate quantile
regression model. The EQ-5D utility scores were categorized into five
quintiles of HRQoL—15th, 30th, 45th, 60th, and 75th—ranging from
poorest to highest HRQoL. The choice of percentiles largely depends
on the research question and the distribution of the outcome. For
example, research interested in the very lowest spectrum may choose
to look at, for example, the 5th, 10th, and 15th quantiles for a fine-
grained analysis at the area of interest. We chose to use the 15th, 30th,
45th , and so on, quantiles because these best fit the distribution of the
data.
Because quantile regression is an extension of the linear regression
model, we used an a priori sample size calculator for multiple regres-
sion to estimate the sample size for the regression at different quantiles
using the formula
Cohen’s f 2 effect size  f 2 
R2
1R2
of 0.07
Thus, at the 15th percentile, we needed 165 patients to detect an
anticipated effect size of 0.07 at 80% power and at the 0.05 significant
level. At the 30th percentile, the required sample was 314. At the 45th
percentile, the required sample size was 245; at the 60th percentile,
the required sample size was 190; and at the 75th percentile, the
required sample size was 249. Given that our sample size was 577,
these power calculations indicated that we had enough power to
detect the association for each quintile.
Regression coefficients for each quantile are provided and repre-
sent the change in EQ-5D utility score per unit change of each cova-
riate for that particular level of HRQoL (see Tables 3, 4). Instead of
having a single regression coefficient for the mean change in outcome,
as in ordinal least squares models, there is a regression coefficient for
each particular quantile of HRQoL. Thus, the change in utility score per
unit change of each covariate alters, depending on which quantile of
HRQoL is being considered. This allows the association between ex-
posure and outcome to be explored across the spectrum of HRQoL.
To examine risk factors associated with utility measures, we ad-
justed for the variables found to be significantly associated with EQ-5D
utility measures in univariate analyses. Despite not being significantly
associated with the EQ-5D in univariate analyses, age was also included
in the models because it is known to be associated with HRQoL. Model
1 adjusted for DR/DME presence and severity, age, income, general
comorbidity, and diabetic complications. Model 2 adjusted for all the
variables in model 1 plus duration of diabetes, insulin use, HDL cho-
lesterol, and BMI. Two-tailed P  0.05 was considered statistically
significant.
RESULTS
A total of 577 patients (379 men; 65.7%) 26 to 90 years of age
(median, 66 years) were included in this analysis. Given that
data for type 1 and type 2 diabetes were almost identical, we
present the results as a combined group. Two-hundred twenty-
three (38.7%) participants had no DR/DME, 35 (6.1%) had mild
NPDR/mild DME, 127 (22.0%) had moderate NPDR/moderate
DME, and 192 (33.3%) had VTDR. Most participants (n  482;
83.5%) reported having type 2 diabetes, and 71 (12.3%) re-
ported having type 1 diabetes (Table 1). The DR/DME group
had higher proportions of men (n  254; 71.8%; P  0.001)
and insulin users (n  194; 55.0%; P  0.001), more diabetic
complications (1 complications: n 140; 39.6%; P 0.001),
and longer median duration of diabetes (18.0; IQR 12.0 years;
P  0.001), and they were significantly younger (63.0  11.1
FIGURE 2. This figure clearly indicates that the regression coefficients
varied at different quantiles of the EQ-5D and proves that applying
traditional statistical models based on an underlying normal distribu-
tion would be inappropriate. Quantile regression, in contrast, which
does not rely on a normally distributed sample, would be a better
approach to study the association between DR/DME and EQ-5D utility
scores.
FIGURE 1. Nonnormal distribution of the EQ-5D utility scores. The
distribution of the EQ-5D is skewed, with 28% of participants having
an EQ-5D score of 1.
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years; P 0.001) than participants without DR/DME (Table 1).
The DR/DME group also had a significantly higher proportion
of persons who were vision impaired and persons who had
higher levels HbA1c, fasting plasma glucose, and HDL choles-
terol (all P  0.05).
Compared with those with no DR/DME, participants with
any DR/DME had a lower EQ-5D utility value (0.80 vs. 0.76; P
0.04) in univariate analysis (Table 2). Higher income and
higher HDL cholesterol were significantly associated with
higher EQ-5D utility values, whereas insulin use, presence of
comorbidity, longer duration of diabetes, and higher BMI were
all associated with lower utility values (all P  0.05). Vision
impairment and severity of DR were not associated with EQ-5D
utility (Table 2).
Because the results from model 1 (presence of any DR/
DME, age, income, presence of comorbidity, and presence of
another diabetic complication) were very similar to those from
model 2 (all the variables in model 1 plus duration of diabetes,
insulin use, HDL cholesterol, and BMI), we report here only on
the best-fitting model (model 2). After adjusting for all variables
in model 2, we found that the presence of any DR/DME was no
longer significantly associated with any quantile of HRQoL (all
P  0.05; Table 3).
In contrast, the presence of one or more other diabetic
complications (  0.153  0.052, P  0.001 in the 75th
quantile), at least one other nonocular comorbidity (
0.115 0.038, P 0.01 in the 60th quantile) and higher BMI
( 0.007  0.002, P  0.001 in the 60th quantile) were all
independently associated with worse HRQoL across various
quantiles. Longer duration of diabetes was also independently
related with poorer HRQoL in the lowest quantile and higher
income was associated with better HRQoL in the highest quan-
tile (Table 3).
We investigated whether severity of DR/DME had a signifi-
cant impact on HRQoL (Table 4) and found that after adjust-
ment for all covariables (model 2), severity of DR/DME was not
TABLE 1. Participants’ Sociodemographic and Clinical Characteristics by DR Status (n  577)
Without DR
(n  223)
With DR*
(n  354)
Pn % n %
Male 125 56.1 254 71.8 <0.001
Income
$30,000 147 71.4 224 66.5
0.24
$30,000 59 28.6 113 33.5
Marital status
Never married 18 11.1 38 13.6
0.45
Married/de facto/divorced/separated/widowed 144 88.9 242 86.4
Education
Primary school or below 34 15.6 46 13.3
0.19Secondary school 113 51.8 207 59.7
14 years or more 71 32.6 94 27.1
Current/past smoker (yes) 125 56.8 193 54.8 0.73
Diabetes type†
1 19 8.5 52 14.7
0.09
2 194 87.0 288 81.4
Insulin use (yes) 45 20.4 194 55.0 <0.001
Number of comorbidities‡
0 24 10.8 54 15.3
0.12
1 199 89.2 300 84.8
Diabetic complications§
0 175 78.5 214 60.5 <0.001
1 48 21.5 140 39.6
Vision impairment (yes) 70 35.6 212 62.7 <0.001
Without DR
(n  223)
With DR*
(n  354)
P
Median or
Mean
IQR or
SD
Median or
Mean
IQR or
SD
Age, y 67.1 12.1 63.0 11.1 <0.001
Systolic blood pressure, mm Hg 137.2 18.1 141.1 19.0 0.99
Diastolic blood pressure, mm Hg 91.3 27.8 93.7 32.7 0.82
Duration of diabetes, y 8.0 9.1 18.0 12.0 <0.001
BMI, kg/m2 30.6 6.4 31.0 6.0 0.74
Fasting plasma glucose, mg/dL 7.2 2.4 8.4 4.4 <0.001
HbA1c, % 7.0 1.4 7.9 1.9 <0.001
HDL cholesterol, mg/dL 1.36 0.55 1.27 0.51 0.006
Data are shown as medians or IQR for skewed data and mean (SD) for normally distributed data. Some variables have missing data. Bold values
indicate significant results.
* Includes any DR and/or DME.
† Twenty-four patients with unknown type of diabetes.
‡ Includes hypertension, heart attack/angina, irregular heartbeat, stroke, high cholesterol, asthma, anemia, migraine, arthritis, and osteo-
porosis.
§ Includes nephropathy, peripheral vascular disease, and neuropathy.
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independently associated with any HRQoL quantile (all P 
0.05). The association between poorer HRQoL and presence of
any diabetic complication other than DR, any nonocular co-
morbidities, and higher BMI maintained their previous signifi-
cant trends, as did the association between higher income and
better HRQoL.
DISCUSSION
Using a robust statistical modeling method, we investigated the
relationship between the presence and severity of DR, DME,
and combined DR/DME, associated vision impairment, and
HRQoL using EQ-5D utility values elicited from a large clinical
sample of adults with type 1 and type 2 diabetes. Data were
almost identical for the three categorizations, and we report
here on the combined DR and DME classification. Our findings
show that neither the presence nor severity of DR/DME or
vision impairment was independently associated with HRQoL
after adjusting for relevant sociodemographic, medical, and
biochemical parameters. In contrast, higher BMI, presence of
comorbidity, and diabetic complications (other than DR) were
significantly associated with worse HRQoL across several quan-
tiles of HRQoL. Higher income was also consistently associated
with better HRQoL in the top spectrum of HRQoL states. Our
findings indicate that the EQ-5D is not suitable for assessing the
impact of the severity of DR/DME and associated vision loss,
and other instruments are needed to provide better assessment
of the impact of this condition on general health parameters.
Our current findings support those from existing studies
showing minimal, nonsignificant differences in EQ-5D utility
values,30–32 15D utility values,33 and SF-6D utility values32 for
diabetic patients with and without DR/DME and pre- and post-
anti-VEGF treatment for DME.34 Our findings are also similar to
those found in other ocular conditions. Espallargues et al., for
example,35 found that the EQ-5D was less sensitive to the
HRQoL burden associated with AMD and related vision loss
than other utility values containing vision-related content.
However, our findings differ from those of previous studies
reporting small but significant decrements in utility values in
patients with DR36 or blindness caused by DR24 and studies
showing a clear association between declining levels of visual
acuity and reduced utility values.14,37 For instance, Smith et al.37
found that the doubling of the visual angle resulted in a modest
but statistically significant loss in utility score of 0.03 in a large
sample of patients with type 2 diabetes (n  154 with visual
acuity worse than 6/12). In addition, our findings do not echo
the comprehensive reductions in QoL caused by to DR-related
vision impairment seen in studies using vision-specific TTO
and SG utility scores.6–9
There are several plausible factors to explain why our find-
ings differ from those of some previous reports. First, we
believe it is likely that generic instruments, such as the EQ-5D,
that do not include a vision-specific dimension in the descrip-
tive system are not sensitive enough to evaluate the specific
burden of DR-induced vision loss and therefore result in un-
derreporting of the impact of the disease. Second, the small
sample sizes of most previous studies, especially with regard to
the more severe spectrum of DR,14,37 could have contributed
to spurious results; our study, in contrast, had a rich clinical
sample of patients with both mild DR and VTDR. Unlike many
other studies, we were able to adjust for important clinical and
sociodemographic variables, thus ensuring that the association
between DR-related vision impairment and utility score was
not confounded by known factors. Indeed, our application of
quantile regression models to the skewed data enhances the
validity of our results and offers a novel and relevant approach
to the field of cost-effectiveness and cost-utility analysis.
Our finding that BMI, comorbidity, and income level are
independently associated with HRQoL status is well supported
by previous studies.38–40 For example, in a state-wide US
study, Jia et al.41 found that obesity/overweight and low in-
TABLE 2. Association between EQ-5D Utility Values and
Sociodemographic and Clinical Variables
EQ-5D Utility Values
Median IQR P
Sex
Male 0.80 0.34 0.10
Female 0.73 0.19
Income
$30,000 0.73 0.26 <0.001
$30,000 0.81 0.31
Marital status
Never married 0.79 0.31 0.33
Married/de facto/divorced/separated/
widowed
0.77 0.38
Education
Primary school or below 0.73 0.23 0.35
Secondary school 0.78 0.31
14 years or more 0.80 0.38
Smoking
Nonsmoker 0.80 0.31 0.19
Current/past smoker 0.76 0.38
Diabetes type*
1 0.76 0.38 0.56
2 0.78 0.34
Insulin use
No 0.80 0.31 0.012
Yes 0.73 0.26
Number of comorbidities†
0 0.85 0.23 <0.001
1 0.73 0.38
Diabetic complications‡
0 0.80 0.31 <0.001
1 0.73 0.23
Vision impairment
No 0.78 0.31 0.27
Yes (0.3 LogMAR) 0.76 0.35
Presence of DR§
No 0.80 0.31 0.04
Any DR 0.76 0.34
Severity of DR
No DR or DME 0.80 0.31 0.24
Mild NPDR, mild DME, or both 0.80 0.48
Moderate NPDR, moderate DME,
or both
0.76 0.31
Vision-threatening DR 0.73 0.38
¶ SE P
Age, y 0.01 0.04 0.87
Systolic blood pressure, mm Hg 0.02 0.04 0.66
Diastolic blood pressure, mm Hg 0.07 0.04 0.08
Duration of diabetes, y 0.13 0.04 0.001
BMI, kg/m2 0.22 0.04 <0.001
Fasting plasma glucose, mg/dL 0.06 0.04 0.15
HbA1c, % 0.07 0.04 0.09
HDL cholesterol, mg/dL 0.13 0.04 0.002
Bold values indicate significant results.
* Twenty-four patients with unknown type of diabetes.
† Includes hypertension, heart attack/angina, irregular heartbeat,
stroke, high cholesterol, asthma, anemia, migraine, arthritis, and osteo-
porosis.
‡ Includes nephropathy, peripheral vascular disease, and neurop-
athy.
§ Includes any DR, DME, or both.
¶ Spearman’s rank correlation coefficient.
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come contributed up to 13.8% and 39.9% of explainable qual-
ity-adjusted life years lost, respectively, calculated using EQ-5D
utility scores. Similarly, Solli et al.,42 investigating the associa-
tion between diabetic complications and EQ-5D, found that
patients with complications from type 2 diabetes had signifi-
cantly lower utility scores than those without any complication
(0.73 vs. 0.85, respectively). Given that the EQ-5D is designed
to assess general HRQoL, it is not surprising that these funda-
mental health-related and sociodemographic variables are
found to be significantly associated with utility score.
The strengths of our study include a large clinical sample of
people with diabetes with differing levels of DR and DME,
especially VTDR, the use of dilated fundus photography and
standardized grading, the use of novel statistical modeling, and
the comprehensive range of demographic and clinical param-
eters included in the analysis. Potential limitations include the
higher proportion of men than women in our sample and the
potential selection biases stemming from our focused recruit-
ment from specialized retinal clinics. In particular, because
DMP participants were primarily recruited from a single source
(the RVEEH), it is possible that the results are not representa-
tive of a general diabetic population. However, because the
DMP sample approximates sociodemographic and clinical
characteristics (e.g., HbA1c level, duration of diabetes, and
blood pressure) found in population-based studies,20 potential
bias is minimized.
Because the DMP study criteria excluded patients with
hearing and cognitive impairment and those who did not live
independently (i.e., those who were likely to have significant
impairment), this might have reduced the sensitivity of the
EQ-5D to measure disutility related to DR/DME. However, the
clinical nature of our study, the extensive testing protocol, and
logistic and financial constraints did not allow us to adequately
address these issues. There are also certain limitations associ-
ated with quantile regression. For example, QALYS cannot be
calculated because they rely on mean utility scores, which are
not provided by quantile regression, and this limits the appli-
cability of the findings. In addition, quantile regression is more
complex than other statistical methods because it requires
bootstrapping methods to produce a large number of estimates
of standard errors of the coefficients. Similarly, the study find-
ings may be more difficult to interpret because of the large
number of regression coefficients produced.
TABLE 3. Association between the Presence of any DR/DME and HRQoL Using Quantile Regression Models for Five Different
Quintiles of HRQoL
Model 2 (n  341)
15th Quantile 30th Quantile 45th Quantile 60th Quantile 75th Quantile
b SE b SE b SE b SE b SE
Presence of any DR or DME 0.043 0.075 0.007 0.030 0.003 0.028 0.018 0.033 0.000 0.027
Age, y 0.006 0.004 0.001 0.002 0.000 0.001 0.001 0.001 0.000 0.001
Income (30,000, 30,000) 0.117 0.085 0.049 0.030 0.034 0.029 0.064 0.030 0.024 0.037
Comorbidities (yes, no)* 0.142 0.072 0.093 0.035 0.092 0.047 0.115 0.038 0.009 0.025
Diabetic complications† 0.213 0.118 0.077 0.030 0.066 0.024 0.059 0.032 0.153 0.052
Duration of diabetes, years 0.011 0.005 0.003 0.002 0.001 0.001 0.002 0.002 0.000 0.001
Insulin use (yes, no) 0.081 0.087 0.022 0.030 0.023 0.024 0.012 0.029 0.000 0.025
BMI, kg/m2 0.006 0.004 0.004 0.002 0.006 0.002 0.007 0.002 0.003 0.003
HDL-C, mmol/L 0.051 0.051 0.027 0.038 0.012 0.034 0.013 0.033 0.009 0.024
Coefficient (b) and standard error (SE) were reported for 15%, 30%, 45%, 60%, and 75%. Coefficients significant at the 5% level are bold; those
at the 1% level are bold and underlined; and those at the 0.1% level are bold, underlined, and italic. Standard errors are obtained using 1000
bootstrap replications.
* Comorbidities include hypertension, heart attack/angina, irregular heart beat, stroke, high cholesterol, asthma, anemia, migraine, arthritis,
and osteoporosis.
† Diabetic complications include nephropathy, peripheral vascular disease, and neuropathy.
TABLE 4. Association between Severity of DR/DME and HRQoL Using Quantile Regression Models for Five Different Quintiles of HRQoL
Model 2 (n  341)
15th Quantile 30th Quantile 45th Quantile 60th Quantile 75th Quantile
b SE b SE b SE b SE b SE
Mild NPDR/mild DME (yes, no) 0.116 0.185 0.017 0.141 0.008 0.077 0.034 0.051 0.007 0.035
Moderate NPDR/moderate DME (yes, no) 0.020 0.129 0.016 0.038 0.017 0.032 0.007 0.041 0.011 0.032
VTDR (yes, no) 0.062 0.076 0.008 0.034 0.010 0.033 0.009 0.037 0.001 0.035
Age, y 0.005 0.003 0.000 0.002 0.000 0.001 0.001 0.001 0.001 0.001
Income (30,000, 30,000) 0.128 0.082 0.049 0.031 0.041 0.029 0.073 0.033 0.022 0.034
Comorbidities (yes, no)* 0.109 0.069 0.087 0.040 0.092 0.046 0.109 0.038 0.009 0.026
Diabetic complications† 0.221 0.119 0.080 0.031 0.071 0.023 0.052 0.033 0.154 0.049
Duration of diabetes, y 0.008 0.005 0.002 0.002 0.001 0.001 0.002 0.002 0.000 0.001
Insulin use (yes, no) 0.055 0.083 0.018 0.029 0.020 0.025 0.028 0.026 0.001 0.001
BMI, kg/m2 0.005 0.004 0.003 0.002 0.006 0.002 0.007 0.002 0.003 0.003
HDL-C, mmol/L 0.042 0.043 0.012 0.041 0.015 0.037 0.004 0.033 0.009 0.027
Coefficient (b) and standard error (SE) were reported for 15%, 30%, 45%, 60%, and 75% quantiles. Coefficients significant at the 5% level are
bold; those at the 1% level are bold and underlined; and those at the 0.1% level are bold, underlined, and italic. Standard errors are obtained using
1000 bootstrap replications.
* Comorbidities include hypertension, heart attack/angina, irregular heartbeat, stroke, high cholesterol, asthma, anemia, migraine, arthritis, and
osteoporosis.
† Diabetic complications include nephropathy, peripheral vascular disease, and neuropathy.
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Another limitation might have been our analysis of type 1
and type 2 diabetes together. However, we did conduct sepa-
rate analyses for our type 2 diabetic sample, and the results
were similar to those of the combined analysis. Our use of
United Kingdom population data to derive EQ-5D utility scores
for an Australian population might also have had an unpredict-
able effect on the results. However, the fact that we were able
to replicate our findings using a New Zealand population set
validates our conclusions.
Our findings have important implications for clinicians and
researchers. We have clearly demonstrated that using generic
HRQoL measures such as the EQ-5D to assess the impact of
vision-related impairment or treatment interventions for ocular
diseases is inappropriate. This is because generic instruments
are developed by drawing items from populations typically
with major medical conditions such as cardiac disease, respi-
ratory disease, and cancer; consequently, they contain very
little or no vision-related content. This is extremely important
because one cannot measure vision-related QoL without vision-
related content. Moreover, any impact of vision impairment or
ocular conditions on generic HRQoL will be lost in the “noise”
of other non-vision–related impacts on QoL in the overall
score.18,43 Recent studies have demonstrated empirically that
some generic instruments cannot capture the impact of vision-
specific impairment and should not be used for this pur-
pose.4,32,44–46
These findings are now extremely relevant to the field of DR
research, in which novel treatment therapies such as anti-VEGF
are emerging. Such novel therapies will have to be compared
with traditional treatments, such as laser photocoagulation and
surgical vitrectomy, in terms of both clinical and patient-cen-
tered outcomes. Similarly, the cost-effectiveness of new treat-
ments may have to be evaluated by policy planners using
quality- and disability-adjusted life years (QALYs and DALYs),
which are calculated from utility values. Therefore, a utility
value that can capture both the impact of DR/DME and the
changes after interventions will be invaluable. Our findings
suggest that the EQ-5D may not be suitable for use in clinical
trials evaluating new DR or DME treatments or for the cal-
culation of QALYs within cost-effectiveness studies. It is
possible, however, that other generic instruments with
greater discriminative ability and a richer descriptive sys-
tem, including vision-related impairment such as the 15D,47
the AQOL-7D48,49 and the HUI-3,50 may be more sensitive to
the specific effects of DR.32
Indeed, we are exploring whether the VisQoL,51,52 a vision-
specific MAUI, can more successfully detect the impact of DR,
DME, and associated vision impairment on vision-related QoL.
The VisQoL was developed and validated specifically for vision-
impaired populations and covers six dimensions of self-re-
ported VRQoL: physical well-being, independence, social well-
being, self-actualization, planning, and organization. As such,
the VisQoL, or any condition-specific MAUI with similar param-
eters assessing relevant QoL issues, is likely to better elucidate
the relationship between DR/DME and patient QoL.
In conclusion, we found that variation in EQ-5D utility
values could not be attributed to the presence or severity of
DR/DME or vision impairment. Rather, general nonocular mor-
bidities were significantly associated with lower utility values
and thus poorer HRQoL. These findings endorse the use of
generic health-related outcome measures by clinicians, re-
searchers, and policy planners to capture the impact of general
social and health-related factors on QoL in patients with diabe-
tes but not to assess the impact of impairment specifically
related to DR, DME, and related vision loss.
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